Trial Profile
A randomized, double-blind, vehicle-controlled, dose-finding, multi-center, phase 2a trial of FOL-005 topical formulations to investigate hair growth potential and safety in healthy male volunteers with androgenetic alopecia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs FOL 005 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Follicum AB
- 15 Sep 2021 According to a Follicum AB media release, following the spring results from this phase 2 study of FOL-005 in the treatment of hair loss, the board decided to evaluate the company's business strategy and long-term goals.
- 03 Jun 2021 According to a Follicum AB media release, It is currently not possible to assess whether the new analysis will result in any reassessment of the conclusions previously drawn on the drug candidates effect on hair loss. Follicum will return as soon as possible with the results of the re-analysis.
- 03 Jun 2021 According to a Follicum AB media release, the contract research organization (CRO) together with Follicum, has discovered possible inaccuracies in the results analysis of this trial . Follicum has hired an independent reviewer who will now review all study data and assess the extent to which this affects the recently reported results.